Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and Exercise

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and Exercise

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mazdutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DREAMS-1
  • Sponsors Innovent Biologics

Most Recent Events

  • 12 Jun 2025 According to an Innovent Biologics Media Release, company will present the results from this study at the American Diabetes Association's (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20-23.
  • 20 Aug 2024 Status changed from active, no longer recruiting to completed.
  • 01 Aug 2024 According to an Innovent Biologics Media Release, company that the second New Drug Application (NDA) of mazdutide has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of adults with type 2 diabetes (T2D) based on the results of two Phase 3 clinical studies (DREAMS-1, NCT05628311 & DREAMS-2, NCT05606913).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top